US › Healthcare

Actuate Therapeutics, Inc. Common stock (ACTU)

US · Healthcare · Biotechnology

$0.33+0.55%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-4.9M

EPS

$-0.20

EPS estimate

$-0.21

EPS came in at -0.20 against a street estimate of -0.21 — a beat of 4.8%.

Key statistics

Market cap

$18.0M

Forward P/E

0.0

P/B

8.33

Book value

$0.04

EPS (TTM)

$-0.81

52-week high

$7.90

52-week low

$0.30

50-day MA

$0.84

200-day MA

$2.08

Beta

1.53

Analyst view

Analysts rate Actuate Therapeutics, Inc. Common stock a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $11.68.

Shareholding

Insiders

14.67%

Institutions

24.54%

Largest institutional holders

Fund	Stake
BIOS CAPITAL MANAGEMENT, LP	41.85%
Voss Capital LLC	7.18%
Vanguard Capital Management, LLC	1.64%
Palogic Value Management LP	0.83%
AQR Capital Management LLC	0.53%
Geode Capital Management, LLC	0.47%
Texas Capital Bank Wealth Management Services Inc	0.43%
Millennium Management LLC	0.40%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Actuate Therapeutics, Inc. Common stock — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.